The U.S. will likely emerge the winner in a "cold currency war" that is heating up, an expert said.Currenciesread more
These box office numbers do not include the cost of production or marketing costs. They also don't count the billions in merchandising that Disney has made over the last...Entertainmentread more
Tariffs are the only instrument left for addressing China's systematic and excessive surpluses on its U.S. trades, writes Michael Ivanovitch.US Economyread more
In its latest attempt to build market credibility, China on Monday launched the Science and Technology Innovation Board, or "STAR Market," on which 25 companies were listed.China Economyread more
When Cathy Hsu and Tony Hsieh wanted to build an English language app for Chinese children, they decided to follow Facebook and Google's lead.Start-upsread more
Stocks in Asia were lower on Monday, as shares on a new Nasdaq-style technology board on the Shanghai Stock Exchange skyrocketed on their debut day.Asia Marketsread more
Instagram began tests that hide "like" counts on posts. That means influencers who market products on Instagram will have to rely on different metrics to show success.Technologyread more
Peter Neupert worked for Microsoft and Amazon-backed Drugstore.com, where he got to know Jeff Bezos. He now advises start-ups.Technologyread more
The firing of the tear gas was the latest confrontation between police and protesters who have taken to the streets for over a month to fight a proposed extradition bill and...China Politicsread more
Last week shows that oil prices are not the indicator for Middle East tensions they once were, and worries about global demand and growing U.S. production has changed that...Market Insiderread more
Facebook Vice President David Marcus is the face of the company's Libra digital currency, but the original driving force was a 26-year-old female corporate-development...Technologyread more
The drug is the second medication of its kind to win FDA approval, following Sprout Pharmaceuticals' Addyi pill, which was cleared in 2015 and stemmed controversy over whether a reduced sex drive in women is considered a health condition or mental issue.
The newly approved drug, bremelanotide, will be marketed under the name Vyleesi and is an injection meant to increase women's libido. It is developed by Palatin Technologies, which granted exclusive licensing rights to Amag Pharmaceuticals.
Unlike Viagra, which directs blood flow to men's genitals, Palatin said Vyleesi works by activating pathways in the brain that are involved in the body's sexual responses. The drug is self-administered through an auto-injector 45 minutes before having sex.
Palatin is set to receive up to $300 million from its deal with Amag if the drug meets certain sales milestones. Palatin will also collect $60 million now that the FDA approved Vyleesi.
Palatin says Vyleesi has undergone more than 30 clinical trials with over 2,500 people. The company said phase 3 studies "confirm the effectiveness" of the drug as a treatment for pre-menopausal women with hypoactive sexual desire disorder. The full trial results have not been made available.
The disorder is a condition in which women lose interest in sex. Experts estimate one in ten women live with the condition.
Vyleesi will join Addyi in women's small list of drug options that can boost their libido. Though the Addyi pill, which is taken daily, was rejected twice by the FDA before winning approval. Doctors originally prohibited alcohol use with the drug, but the company now says new data shows it's safe to take with alcohol.